Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the clinical study results of 9MW3011 will be presented in a poster presentation at the 2024 European Hematology Association (EHA2024) Congress. As one of the largest international meetings of hematology in the world, EHA2024 will be held in Madrid, Spain, from June 13-16, 2024.

Poster Presentation

Abstract Title：SINGLE ASCENDING DOSES OF 9MW3011, A MONOCLONAL ANTIBODY TARGETING TMPRSS6, RESULT IN SUSTAINED ELEVATION OF SERUM HEPCIDIN AND REDUCTION OF IRON LEVELS IN HEALTHY VOLUNTEERS

Abstract Code：P1568

About 9MW3011

9MW3011 is an anti-TMPRSS6 antibody developed at San Diego Innovation and R&D Center of Mabwell. 9MW3011 can upregulate the level of hepcidin expressed by hepatocytes through specific binding, inhibit the absorption and release of iron, and lower the serum iron level, thus regulating the iron homeostasis in vivo. The proposed indications of 9MW3011 include β-thalassemia and polycythemia vera. At present, there are no mature and effective macromolecular drug for relevant indications. FDA has granted Fast Track Designation and Orphan Drug Designation to 9MW3011.

Mabwell has granted DISC Medicine, INC. (NASDAQ：IRON) exclusive rights to develop and commercialize 9MW3011 in the United States, Europe, and other territories excluding Great China and Southeast Asia. Mabwell will obtain a total of up to $412.5 million of down payment and milestone payments, as well as royalties on net sales.

About European Hematology Association Annual Congress

The European Hematology Association (EHA) annual congress is one of the largest international meetings in the field of hematology in the world, with more than 10,000 professionals from over 100 countries attending each year to share and discuss innovative ideas and the latest scientific and clinical findings in hematology. EHA aims to promote the dissemination of science and knowledge in fundamental, translational and clinical research in hematology in Europe.